This Article Full Text Full Text (PDF) All Versions of this Article: bjo.2007.122283v1 bjo.2007.122283v2 92/1/70    most recent Submit a response Read responses to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gomi, F Articles by Tano, Y Search for Related Content PubMed PubMed Citation Articles by Gomi, F Articles by Tano, Y

Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy

Department of Ophthalmology, Osaka University Medical School, Osaka, Japan

Correspondence to:
Fumi Gomi, Department of Ophthalmology, Osaka University Medical School, 2-2 Yamada-oka, Suita, Osaka 565-0871, Japan; fgomi{at}ophthal.med.osaka-u.ac.jp

Aims: The aim of the study was to assess the short-term efficacy of intravitreal injections of bevacizumab for polypoidal choroidal vasculopathy (PCV).

Methods: Intravitreal bevacizumab (1 mg) was injected into 11 eyes of 11 patients with PCV in this retrospective, interventional case series. The main outcome measure was the change in the polypoidal vessels on indocyanine green angiography (IA) 3 months after injection. The foveal height determined by optical coherence tomography and the best-corrected visual acuity (BCVA) also were evaluated before and after treatment.

Results: At baseline, subretinal fluid was observed in five eyes and a pigment epithelial detachment in eight eyes. The foveal height 1 month after injection decreased significantly (p = 0.023), but at 3 months, no significant decrease was observed, although an additional injection was administrated in five of 11 eyes. The IA at 3 months showed resolution of polyps in one eye but residual or enlarged lesions in the other ten eyes. The BCVA did not improve significantly, although the subjects had relatively good BCVA at baseline (mean 0.45).

Conclusion: Intravitreal injection of bevacizumab may reduce the fluid from PCV but seems to be ineffective for diminishing its choroidal vascular changes.

Competing interests: None.

This article has been cited by other articles:

				T Wakabayashi, F Gomi, M Sawa, M Tsujikawa, and Y Tano Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy Br. J. Ophthalmol., July 1, 2008; 92(7): 936 - 940. [Abstract] [Full Text] [PDF]

				T Y Y Lai, W-M Chan, D T L Liu, F O J Luk, and D S C Lam Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy Br. J. Ophthalmol., May 1, 2008; 92(5): 661 - 666. [Abstract] [Full Text] [PDF]

eLetters: